Manning & Napier Advisors LLC Trims Stock Holdings in Novo Nordisk A/S $NVO

Manning & Napier Advisors LLC cut its holdings in shares of Novo Nordisk A/S (NYSE:NVO) by 8.4% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 166,932 shares of the company’s stock after selling 15,269 shares during the quarter. Manning & Napier Advisors LLC’s holdings in Novo Nordisk A/S were worth $8,550,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. Guerra Advisors Inc acquired a new stake in Novo Nordisk A/S during the 3rd quarter valued at approximately $25,000. Strengthening Families & Communities LLC purchased a new position in shares of Novo Nordisk A/S during the 3rd quarter valued at about $30,000. WealthCollab LLC raised its stake in shares of Novo Nordisk A/S by 93.5% during the 4th quarter. WealthCollab LLC now owns 538 shares of the company’s stock valued at $27,000 after buying an additional 260 shares during the last quarter. American National Bank & Trust purchased a new position in shares of Novo Nordisk A/S during the 4th quarter valued at about $28,000. Finally, Jackson Grant Investment Advisers Inc. purchased a new position in shares of Novo Nordisk A/S during the 4th quarter valued at about $29,000. 11.54% of the stock is currently owned by institutional investors and hedge funds.

Novo Nordisk A/S Price Performance

NYSE:NVO opened at $46.02 on Friday. The firm has a market cap of $205.47 billion, a price-to-earnings ratio of 10.80, a price-to-earnings-growth ratio of 10.74 and a beta of 0.77. Novo Nordisk A/S has a 1-year low of $35.12 and a 1-year high of $81.44. The company has a debt-to-equity ratio of 0.59, a current ratio of 0.79 and a quick ratio of 0.57. The company has a 50 day moving average price of $38.71 and a 200-day moving average price of $46.97.

Novo Nordisk A/S (NYSE:NVO) last issued its quarterly earnings results on Tuesday, March 31st. The company reported $1.03 earnings per share (EPS) for the quarter. Novo Nordisk A/S had a return on equity of 63.31% and a net margin of 37.23%.The company had revenue of $10.85 billion for the quarter. Equities research analysts forecast that Novo Nordisk A/S will post 3.39 EPS for the current year.

Trending Headlines about Novo Nordisk A/S

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Wegovy pill demand is surging, with reports of a “record-breaking” U.S. launch and more than 2 million prescriptions since January, strengthening confidence in Novo Nordisk’s growth outlook. Novo’s CEO champions “record-breaking start” for Wegovy pill in US market
• Positive Sentiment: Novo Nordisk raised its 2026 guidance after strong oral Wegovy prescriptions, suggesting the new formulation could offset some pricing pressure and support profits. Novo Nordisk Guidance Lift Tests Valuation As Oral Wegovy Demand Surges
• Positive Sentiment: Amazon is expanding access to Novo Nordisk’s Ozempic pill through same-day delivery and kiosks, which could broaden patient reach and improve adoption. Amazon Pharmacy Expands Access to New Ozempic® Pill via Same-Day Delivery, Kiosks
• Positive Sentiment: Analysts are lifting earnings estimates, reflecting confidence that the company’s recent momentum can carry into the next fiscal year. Hims & Hers Earnings Preview: The Novo Nordisk Shift Puts GLP-1 Strategy in Focus (NVO)
• Neutral Sentiment: Novo’s India sales jumped after price cuts boosted demand, but the growth also highlights intensifying competition from cheaper GLP-1 alternatives in key international markets. Novo Nordisk’s Ozempic India Price Cut Boosts Obesity Drug Sales
• Neutral Sentiment: Broader investor focus remains on whether the Wegovy pill can expand the GLP-1 market enough to offset pricing pressure and competition from Eli Lilly. Novo and Lilly gain on signs weight-loss pills could expand the market
• Negative Sentiment: Generic Ozempic competition is beginning to emerge in Canada, raising concern that semaglutide revenue could weaken internationally over time. Healthy Returns: First Ozempic generics in Canada will be a test case for Novo Nordisk

Analyst Upgrades and Downgrades

NVO has been the subject of a number of recent research reports. Morgan Stanley upgraded Novo Nordisk A/S from an “underweight” rating to an “equal weight” rating and set a $40.00 price objective for the company in a research note on Tuesday, March 3rd. Weiss Ratings lowered Novo Nordisk A/S from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Wednesday, April 22nd. Sanford C. Bernstein initiated coverage on Novo Nordisk A/S in a research note on Wednesday, March 18th. They set an “outperform” rating and a $175.00 price objective for the company. TD Cowen lowered Novo Nordisk A/S from a “buy” rating to a “hold” rating and set a $42.00 price objective for the company. in a research note on Tuesday, March 10th. Finally, Kepler Capital Markets lowered shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating in a report on Tuesday, February 24th. Four investment analysts have rated the stock with a Buy rating, eighteen have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $65.56.

About Novo Nordisk A/S

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.